Telomerase in the early detection of cancer

J W Shay, A F Gazdar, J W Shay, A F Gazdar

Abstract

Although there is justifiable optimism regarding telomerase activity and early detection of cancer, it is important to point out that there is much that remains to be understood and additional validation studies will be required before knowledge of telomerase activity will be useful in decisions regarding patient management. A key question is whether we will be able to distinguish those cancers that are going to progress from those cancers that are not by detecting telomerase activity. Molecular staging using markers such as telomerase activity in combination with other molecular markers may be particularly useful in this regard. Basic scientists and clinicians must work together if this strategy is to mature. Telomerase inhibitors in the treatment of cancer are awaited with great anticipation.

References

    1. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2882-5
    1. Clin Cancer Res. 1996 May;2(5):799-803
    1. Cell. 1994 Jun 3;77(5):621-3
    1. Curr Opin Genet Dev. 1994 Apr;4(2):203-11
    1. EMBO J. 1994 Oct 17;13(20):4953-62
    1. Science. 1994 Dec 23;266(5193):2011-5
    1. Blood. 1995 May 1;85(9):2315-20
    1. Cancer Res. 1995 Jun 15;55(12):2533-6
    1. Cancer Res. 1995 Jul 1;55(13):2734-6
    1. Cancer Res. 1995 Aug 1;55(15):3258-62
    1. Science. 1995 Sep 1;269(5228):1236-41
    1. J Natl Cancer Inst. 1995 Jun 21;87(12):895-902
    1. J Immunol. 1995 Oct 15;155(8):3711-5
    1. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9082-6
    1. EMBO J. 1995 Sep 1;14(17):4240-8
    1. Nucleic Acids Res. 1995 Sep 25;23(18):3794-5
    1. Lancet. 1995 Nov 11;346(8985):1267-8
    1. Nat Med. 1995 Mar;1(3):249-55
    1. Cancer Res. 1996 Jan 1;56(1):218-22
    1. J Natl Cancer Inst. 1996 Jan 17;88(2):116-22
    1. J Invest Dermatol. 1996 Apr;106(4):759-65
    1. EMBO J. 1996 Apr 1;15(7):1734-41
    1. Mol Cell Biol. 1996 Jun;16(6):2932-9
    1. Am J Pathol. 1996 Apr;148(4):1075-9
    1. Stem Cells. 1996 Mar;14(2):239-48
    1. Dokl Akad Nauk SSSR. 1971;201(6):1496-9
    1. Nat New Biol. 1972 Oct 18;239(94):197-201
    1. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6
    1. Cell. 1989 Nov 3;59(3):521-9
    1. Nature. 1991 Apr 18;350(6319):569-73
    1. Mutat Res. 1991 Mar-Nov;256(2-6):271-82
    1. EMBO J. 1992 May;11(5):1921-9
    1. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8
    1. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6476-81
    1. Oncogene. 1996 Jul 4;13(1):161-6
    1. Leukemia. 1996 Aug;10(8):1255-61
    1. Cancer Res. 1996 Aug 1;56(15):3530-3
    1. Int J Cancer. 1996 Aug 22;69(4):301-6
    1. Curr Opin Oncol. 1996 Jan;8(1):66-71
    1. Trends Genet. 1996 Apr;12(4):127-8
    1. Trends Genet. 1996 Apr;12(4):129-31
    1. Dev Genet. 1996;18(2):173-9
    1. Nat Biotechnol. 1996 May;14(5):615-9
    1. Nat Biotechnol. 1996 Jul;14(7):836-9
    1. Clin Cancer Res. 1995 Nov;1(11):1245-51
    1. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2900-4

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere